KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Receivables (2016 - 2025)

NovoCure's Receivables history spans 12 years, with the latest figure at $66.5 million for Q4 2025.

  • For Q4 2025, Receivables rose 62.93% year-over-year to $66.5 million; the TTM value through Dec 2025 reached $66.5 million, up 62.93%, while the annual FY2025 figure was $66.5 million, 62.93% up from the prior year.
  • Receivables for Q4 2025 was $66.5 million at NovoCure, up from $46.7 million in the prior quarter.
  • Across five years, Receivables topped out at $97.6 million in Q2 2022 and bottomed at $17.0 million in Q4 2021.
  • The 5-year median for Receivables is $55.9 million (2023), against an average of $54.6 million.
  • The largest annual shift saw Receivables crashed 82.39% in 2021 before it soared 443.65% in 2022.
  • A 5-year view of Receivables shows it stood at $17.0 million in 2021, then soared by 65.35% to $28.2 million in 2022, then fell by 4.34% to $26.9 million in 2023, then soared by 51.47% to $40.8 million in 2024, then surged by 62.93% to $66.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Receivables are $66.5 million (Q4 2025), $46.7 million (Q3 2025), and $46.1 million (Q2 2025).